High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.

<h4>Objectives</h4>We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.<h4>Methods</...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jason M Cota, Taylor M Benavides, John D Fields, Nathan Jansen, Anuradha Ganesan, Rhonda E Colombo, Jason M Blaylock, Ryan C Maves, Brian K Agan, Jason F Okulicz
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b77ac608004b4c3eb908b71015873297
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b77ac608004b4c3eb908b71015873297
record_format	dspace
spelling	oai:doaj.org-article:b77ac608004b4c3eb908b710158732972021-12-02T20:05:42ZHigh frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.1932-620310.1371/journal.pone.0250607https://doaj.org/article/b77ac608004b4c3eb908b710158732972021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0250607https://doaj.org/toc/1932-6203<h4>Objectives</h4>We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.<h4>Methods</h4>Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode.<h4>Results</h4>A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1-12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85-5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83-3.64).<h4>Conclusions</h4>PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens.Jason M CotaTaylor M BenavidesJohn D FieldsNathan JansenAnuradha GanesanRhonda E ColomboJason M BlaylockRyan C MavesBrian K AganJason F OkuliczPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0250607 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jason M Cota Taylor M Benavides John D Fields Nathan Jansen Anuradha Ganesan Rhonda E Colombo Jason M Blaylock Ryan C Maves Brian K Agan Jason F Okulicz High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
description	<h4>Objectives</h4>We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.<h4>Methods</h4>Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode.<h4>Results</h4>A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1-12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85-5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83-3.64).<h4>Conclusions</h4>PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens.
format	article
author	Jason M Cota Taylor M Benavides John D Fields Nathan Jansen Anuradha Ganesan Rhonda E Colombo Jason M Blaylock Ryan C Maves Brian K Agan Jason F Okulicz
author_facet	Jason M Cota Taylor M Benavides John D Fields Nathan Jansen Anuradha Ganesan Rhonda E Colombo Jason M Blaylock Ryan C Maves Brian K Agan Jason F Okulicz
author_sort	Jason M Cota
title	High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
title_short	High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
title_full	High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
title_fullStr	High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
title_full_unstemmed	High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
title_sort	high frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with hiv infection and erectile dysfunction.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/b77ac608004b4c3eb908b71015873297
work_keys_str_mv	AT jasonmcota highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT taylormbenavides highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT johndfields highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT nathanjansen highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT anuradhaganesan highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT rhondaecolombo highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT jasonmblaylock highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT ryancmaves highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT briankagan highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction AT jasonfokulicz highfrequencyofpotentialphosphodiesterasetype5inhibitordruginteractionsinmaleswithhivinfectionanderectiledysfunction
_version_	1718375444989870080

High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.

Ejemplares similares